Details of the Drug

General Information of Drug (ID: DMS90CU)

Drug Name
SGN-CD19A
Synonyms Denintuzumab mafodotin
Indication
Disease Entry ICD 11 Status REF
Diffuse large B-cell lymphoma 2A81 Phase 2 [1]
Acute lymphoblastic leukaemia 2A85 Phase 1 [2]
Non-hodgkin lymphoma 2B33.5 Phase 1 [2]
Structure
3D MOL is unavailable 2D MOL
Chemical Identifiers
Formula
C52H83N7O13S
Canonical SMILES
CCC(C)C(C(CC(=O)N1CCCC1C(C(C)C(=O)NC(CC2=CC=CC=C2)C(=O)O)OC)OC)N(C)C(=O)C(C(C)C)NC(=O)C(C(C)C)N(C)C(=O)CCCCCN3C(=O)CC(C3=O)SCC(C(=O)O)N
InChI
1S/C52H83N7O13S/c1-12-32(6)45(38(71-10)27-41(61)58-25-19-22-37(58)46(72-11)33(7)47(63)54-36(52(69)70)26-34-20-15-13-16-21-34)57(9)50(66)43(30(2)3)55-48(64)44(31(4)5)56(8)40(60)23-17-14-18-24-59-42(62)28-39(49(59)65)73-29-35(53)51(67)68/h13,15-16,20-21,30-33,35-39,43-46H,12,14,17-19,22-29,53H2,1-11H3,(H,54,63)(H,55,64)(H,67,68)(H,69,70)/t32-,33+,35-,36-,37-,38+,39?,43-,44-,45-,46+/m0/s1
InChIKey
BXTJCSYMGFJEID-XMTADJHZSA-N
Cross-matching ID
PubChem CID
86278355
CAS Number
1165741-01-4
TTD ID
D0UT5A
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

References

1 ClinicalTrials.gov (NCT02855359) Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma. U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT01786135) A Safety Study of SGN-CD19A for B-Cell Lymphoma. U.S. National Institutes of Health.